Dataset Information

Evaluating the utility of digital phenotyping to predict health outcomes in schizophrenia: protocol for the HOPE-S observational study.

ABSTRACT:

Introduction

The course of schizophrenia illness is characterised by recurrent relapses which are associated with adverse clinical outcomes such as treatment-resistance, functional and cognitive decline. Early identification is essential and relapse prevention remains a primary treatment goal for long-term management of schizophrenia. With the ubiquity of devices such as smartphones, objective digital biomarkers can be harnessed and may offer alternative means for symptom monitoring and relapse prediction. The acceptability of digital sensors (smartphone and wrist-wearable device) and the association between the captured digital data with clinical and health outcomes in individuals with schizophrenia will be examined.

Methods and analysis

In this study, we aim to recruit 100 individuals with schizophrenia spectrum disorders who are recently discharged from the Institute of Mental Health (IMH), Singapore. Participants are followed up for 6 months, where digital, clinical, cognitive and functioning data are collected while health utilisation data are obtained at the 6 month and 1 year timepoint from study enrolment. Associations between digital, clinical and health outcomes data will be examined. A data-driven machine learning approach will be used to develop prediction algorithms to detect clinically significant outcomes. Study findings will inform the design, data collection procedures and protocol of future interventional randomised controlled trial, testing the effectiveness of digital phenotyping in clinical management of individuals with schizophrenia spectrum disorders.

Ethics and dissemination

Ethics approval has been granted by the National Healthcare Group (NHG) Domain Specific Review Board (DSRB Reference no.: 2019/00720). The results will be published in peer-reviewed journals and presented at conferences.

Trial registration number

NCT04230590.

SUBMITTER: Abdul Rashid NA

PROVIDER: S-EPMC8529971 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Evaluating the utility of digital phenotyping to predict health outcomes in schizophrenia: protocol for the HOPE-S observational study.

Abdul Rashid Nur Amirah NA Martanto Wijaya W Yang Zixu Z Wang Xuancong X Heaukulani Creighton C Vouk Nikola N Buddhika Thisum T Wei Yuan Y Verma Swapna S Tang Charmaine C Morris Robert J T RJT Lee Jimmy J

BMJ open 20211020 10

<h4>Introduction</h4>The course of schizophrenia illness is characterised by recurrent relapses which are associated with adverse clinical outcomes such as treatment-resistance, functional and cognitive decline. Early identification is essential and relapse prevention remains a primary treatment goal for long-term management of schizophrenia. With the ubiquity of devices such as smartphones, objective digital biomarkers can be harnessed and may offer alternative means for symptom monitoring and ...[more]

PMID: 34670760

Similar Datasets

Project description:BackgroundDigital phenotyping provides insights into an individual's digital behaviors and has potential clinical utility.ObjectiveIn this observational study, we explored digital biomarkers collected from wrist-wearable devices and smartphones and their associations with clinical symptoms and functioning in patients with schizophrenia.MethodsWe recruited 100 outpatients with schizophrenia spectrum disorder, and we collected various digital data from commercially available wrist wearables and smartphones over a 6-month period. In this report, we analyzed the first week of digital data on heart rate, sleep, and physical activity from the wrist wearables and travel distance, sociability, touchscreen tapping speed, and screen time from the smartphones. We analyzed the relationships between these digital measures and patient baseline measurements of clinical symptoms assessed with the Positive and Negative Syndrome Scale, Brief Negative Symptoms Scale, and Calgary Depression Scale for Schizophrenia, as well as functioning as assessed with the Social and Occupational Functioning Assessment Scale. Linear regression was performed for each digital and clinical measure independently, with the digital measures being treated as predictors.ResultsDigital data were successfully collected from both the wearables and smartphones throughout the study, with 91% of the total possible data successfully collected from the wearables and 82% from the smartphones during the first week of the trial-the period under analysis in this report. Among the clinical outcomes, negative symptoms were associated with the greatest number of digital measures (10 of the 12 studied here), followed by overall measures of psychopathology symptoms, functioning, and positive symptoms, which were each associated with at least 3 digital measures. Cognition and cognitive/disorganization symptoms were each associated with 1 or 2 digital measures.ConclusionsWe found significant associations between nearly all digital measures and a wide range of symptoms and functioning in a community sample of individuals with schizophrenia. These findings provide insights into the digital behaviors of individuals with schizophrenia and highlight the potential of using commercially available wrist wearables and smartphones for passive monitoring in schizophrenia.

Project description:The promise of machine learning successfully exploiting digital phenotyping data to forecast mental states in psychiatric populations could greatly improve clinical practice. Previous research focused on binary classification and continuous regression, disregarding the often ordinal nature of prediction targets derived from clinical rating scales. In addition, mental health ratings typically show important class imbalance or skewness that need to be accounted for when evaluating predictive performance. Besides it remains unclear which machine learning algorithm is best suited for forecast tasks, the eXtreme Gradient Boosting (XGBoost) and long short-term memory (LSTM) algorithms being 2 popular choices in digital phenotyping studies. The CrossCheck dataset includes 6,364 mental state surveys using 4-point ordinal rating scales and 23,551 days of smartphone sensor data contributed by patients with schizophrenia. We trained 120 machine learning models to forecast 10 mental states (e.g., Calm, Depressed, Seeing things) from passive sensor data on 2 predictive tasks (ordinal regression, binary classification) with 2 learning algorithms (XGBoost, LSTM) over 3 forecast horizons (same day, next day, next week). A majority of ordinal regression and binary classification models performed significantly above baseline, with macro-averaged mean absolute error values between 1.19 and 0.77, and balanced accuracy between 58% and 73%, which corresponds to similar levels of performance when these metrics are scaled. Results also showed that metrics that do not account for imbalance (mean absolute error, accuracy) systematically overestimated performance, XGBoost models performed on par with or better than LSTM models, and a significant yet very small decrease in performance was observed as the forecast horizon expanded. In conclusion, when using performance metrics that properly account for class imbalance, ordinal forecast models demonstrated comparable performance to the prevalent binary classification approach without losing valuable clinical information from self-reports, thus providing richer and easier to interpret predictions.

Dataset Information

Evaluating the utility of digital phenotyping to predict health outcomes in schizophrenia: protocol for the HOPE-S observational study.

Introduction

Methods and analysis

Ethics and dissemination

Trial registration number

Publications

Evaluating the utility of digital phenotyping to predict health outcomes in schizophrenia: protocol for the HOPE-S observational study.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets